Afrezza: Fast-Acting Inhaled Insulin
Links to Files
https://ezproxy.stevenson.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=107830773&site=eds-live&scope=sitePermanent Link
http://dx.doi.org/10.1097/01.NAJ.0000454844.50727.76http://hdl.handle.net/11603/5650
Collections
Metadata
Show full item recordAuthor/Creator
Date
2014-10Type of Work
2 pagesText
journal articles
Department
Sandra R. Berman School of Nursing and Health ProfessionsProgram
NursingCitation of Original Publication
Aschenbrenner, D. S. (2014). Afrezza: Fast-acting inhaled insulin. American Journal Of Nursing, 114(10), 22-23. doi:10.1097/01.NAJ.0000454844.50727.76Abstract
Afrezza (insulin human) is a newly approved fast-acting inhaled insulin. It can be used in treating type 1 diabetes when added to a long-acting insulin; in studies, patients with type 2 diabetes used it in combination with oral antidiabetic therapy. Afrezza will be available in 2015. Afrezza is taken before meals using a small, specially designed inhaler. Patients should be carefully assessed for lung disease prior to starting Afrezza therapy. Chronic obstructive pulmonary disease and asthma are contraindications to use. Lung function can deteriorate after therapy begins.